CorrespondenceLevofloxacin prophylaxis in patients with myeloma
References (5)
- et al.
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Lancet Oncol
(2019) - et al.
Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
Crit Rev Oncol Hematol
(2019)
There are more references available in the full text version of this article.
Cited by (5)
Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel
2022, Critical Reviews in Oncology/HematologyCitation Excerpt :This study demonstrated that levofloxacin administered for 12 weeks significantly reduced febrile episodes compared with placebo without inducing new acquisition of antibiotic-resistant bacteria. However, there was no significant difference in overall survival, which highlighted concerns regarding the study design and conclusions (Albrich and Boggian, 2020; Teh et al., 2020). Thus, although widespread use of quinolone prophylaxis in all myeloma patients undergoing treatment does not seem an appropriate practice, antibacterial prophylaxis might be justified in the first few months of treatment of myeloma patients, when the disease burden and the risk of severe infections are high.
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation
2022, Cancer and Metastasis Reviews
© 2020 Elsevier Ltd. All rights reserved.